Enzo Biochem v. Gen-Probe:: Complying with the written description requirement under US patent law

被引：0

作者：

Blaug, S

Shuster, M

Su, H

机构：

[1] Fenwick & West LLP, Silicon Valley Ctr, Mountain View, CA 94041 USA

[2] Fenwick & West LLP, San Francisco, CA 94111 USA

来源：

NATURE BIOTECHNOLOGY | 2003年 / 21卷 / 01期

关键词：

D O I：

10.1038/nbt0103-97

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Recent court decisions effectively call for researchers and companies to reduce their biotechnology and pharmaceutical inventions to practice before they can apply for patent protection.

引用

页码：97 / 99

页数：3

共 4 条

[1] Enzo Biochem v. Gen-Probe: Complying with the written description requirement under US patent law
Sasha Blaug
Michael Shuster
Henry Su
[J]. Nature Biotechnology, 2003, 21 : 97 - 99
[2] Complying with the statutory written description requirement in a US utility patent application
Silverman, AB
[J]. JOM-JOURNAL OF THE MINERALS METALS & MATERIALS SOCIETY, 2003, 55 (06): : 80 - 80
[3] US federal circuit determines a written description requirement separate from the enablement requirement in US patent law
Macphail, Stuart
[J]. Industrial Biotechnology, 2010, 6 (06) : 330 - 334
[4] How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement-A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.
Chen, Ping-Hsun
[J]. BIOTECHNOLOGY LAW REPORT, 2022, 41 (05) : 240 - 250

← 1 →